Chemical industry – Page 71
-
Business
US import ban imposed on Indian pharma firm
Concerns over manufacturing processes at Emcure facility prompts Food and Drug Administration to block drug shipments
-
Business
US chemical maker Platform expands with Alent purchase
Platform Specialty Products plans to enlarge its scope and reach by acquiring British chemicals firm Alent for $2.1bn
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
Business
Thermo Fisher to buy Alfa Aesar chemical supplies
Research chemicals business no longer a strategic fit for owner Johnson Matthey
-
Business
Blast kills six at South Korean chemical plant
One further worker injured as tank explodes during welding work
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
Job cuts at Allergan and Transgene
Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs
-
Business
Fracking prohibited in New York state and Lancashire
Local US and UK rulings prohibit shale oil drilling and exploration
-
Business
Allergan to buy Kythera Biopharma for $2.1bn
Acquisition strengthens firm’s position in cosmetic treatments with only drug approved for a ‘double chin’
-
OpinionMissing the target
There are plenty of things that small molecule drugs can’t touch, says Derek Lowe, and it’s not for want of trying
-
BusinessSafer substitutes show growth potential
The global market for alternative products based on ‘green’ chemistry is growing fast, fuelled by regulation and consumer demand
-
Business
Alnylam accuses Dicerna of stealing trade secrets
Firm claims rights to GalNAc conjugated siRNA technology acquired from Merck & Co
-
Business
Suspect suicide won’t end trade secret theft probe
An ex-PPG chemist who was arrested for selling trade secrets to a Chinese firm has killed himself, but the Justice Department will continue its investigation
-
BusinessCompanies clamour for CAR-T
Engineered immune cell therapies show promise in early cancer trials, prompting firms to compete for a foothold in the field
-
-
NewsSecurity experts warn chemical plants are vulnerable to cyber-attacks
Action is needed to protect chemical plants and other infrastructure from hackers
-
Business
Vertex nabs rights to cystic fibrosis molecules
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs
-
Business
Opko deepens diagnostics with $1.5bn lab buyout
Taking over clinical diagnostics service provider BioReference Laboratories gives Opko a bigger avenue to distribute and market its diagnostic tests
-
BusinessBMS sues executive for joining rival company
Bristol-Myers Squibb’s lawsuit against its former immuno-oncology chief who left to work for AstraZeneca has implications for biopharma industry